UY32822A - Composiciones farmacéuticas para el tratamiento de cáncer y otras enfermedades o trastornos - Google Patents
Composiciones farmacéuticas para el tratamiento de cáncer y otras enfermedades o trastornosInfo
- Publication number
- UY32822A UY32822A UY32822A UY32822A UY32822A UY 32822 A UY32822 A UY 32822A UY 32822 A UY32822 A UY 32822A UY 32822 A UY32822 A UY 32822A UY 32822 A UY32822 A UY 32822A
- Authority
- UY
- Uruguay
- Prior art keywords
- disorders
- cancer
- diseases
- treatment
- production
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000002552 dosage form Substances 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- 238000012769 bulk production Methods 0.000 abstract 1
- 230000012292 cell migration Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23021209P | 2009-07-31 | 2009-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY32822A true UY32822A (es) | 2011-01-31 |
Family
ID=42697590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY32822A UY32822A (es) | 2009-07-31 | 2010-08-02 | Composiciones farmacéuticas para el tratamiento de cáncer y otras enfermedades o trastornos |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US20110039826A1 (enExample) |
| EP (1) | EP2459173B1 (enExample) |
| JP (2) | JP2013500965A (enExample) |
| KR (1) | KR101762285B1 (enExample) |
| CN (2) | CN102548539A (enExample) |
| AR (1) | AR077436A1 (enExample) |
| AU (1) | AU2010276741B2 (enExample) |
| BR (1) | BR112012002265B8 (enExample) |
| CA (1) | CA2769531C (enExample) |
| CL (1) | CL2012000261A1 (enExample) |
| CO (1) | CO6612185A2 (enExample) |
| CR (1) | CR20120084A (enExample) |
| EA (1) | EA025277B1 (enExample) |
| EC (1) | ECSP12011703A (enExample) |
| GE (1) | GEP201606513B (enExample) |
| IL (1) | IL217839A (enExample) |
| IN (1) | IN2012DN01237A (enExample) |
| JO (1) | JO3434B1 (enExample) |
| MA (1) | MA33533B1 (enExample) |
| MX (2) | MX2012001196A (enExample) |
| MY (1) | MY174084A (enExample) |
| NZ (1) | NZ598096A (enExample) |
| PE (1) | PE20120788A1 (enExample) |
| SG (2) | SG10201404483VA (enExample) |
| TN (1) | TN2012000046A1 (enExample) |
| TW (1) | TWI522357B (enExample) |
| UA (1) | UA110463C2 (enExample) |
| UY (1) | UY32822A (enExample) |
| WO (1) | WO2011014248A1 (enExample) |
| ZA (1) | ZA201200944B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101792651B1 (ko) * | 2004-05-14 | 2017-11-20 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 아우로라 키나아제의 억제에 의해 유사분열 진행을 억제하기 위한 화합물 및 그 화합물을 포함하는 약학적 조성물 |
| CN102264368B (zh) | 2008-12-22 | 2014-09-10 | 米伦纽姆医药公司 | 极光激酶抑制剂与抗cd20抗体的组合 |
| JO3635B1 (ar) | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
| JO3434B1 (ar) | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
| TWI392514B (zh) * | 2010-01-29 | 2013-04-11 | Colgate Palmolive Co | 具有高微生物效力之不含氟化物及陰離子表面活性劑的潔牙劑 |
| WO2011103089A1 (en) | 2010-02-19 | 2011-08-25 | Millennium Pharmaceuticals, Inc. | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6--methoxyphenyl)-5h -pyrimido[5,4-d][2]benzazepin-2yl]amino}-2-methoxybenzoate |
| AR086656A1 (es) | 2011-06-03 | 2014-01-15 | Millennium Pharm Inc | Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a |
| US20130303519A1 (en) | 2012-03-20 | 2013-11-14 | Millennium Pharmaceuticals, Inc. | Methods of treating cancer using aurora kinase inhibitors |
| EP2976086B1 (en) | 2013-03-22 | 2020-10-14 | Millennium Pharmaceuticals, Inc. | Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase |
| US10335494B2 (en) | 2013-12-06 | 2019-07-02 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-CD30 antibodies |
| EP3324976A4 (en) | 2015-07-21 | 2019-03-27 | Millennium Pharmaceuticals, Inc. | ADMINISTRATION OF KINASE AURORA INHIBITOR AND CHEMOTHERAPEUTIC AGENTS |
| USD797120S1 (en) | 2015-08-28 | 2017-09-12 | Samsung Electronics Co., Ltd. | Display screen or portion thereof with graphical user interface |
| IL327467A (en) | 2023-10-03 | 2026-05-01 | Takeda Pharmaceutical Co Limited | Elisartib and paclitaxel for the treatment of small cell lung cancer |
| WO2025245045A1 (en) | 2024-05-21 | 2025-11-27 | The Regents Of The University Of California | Methods of treating lung cancer |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747487A (en) * | 1993-07-29 | 1998-05-05 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| AU5330698A (en) | 1996-12-23 | 1998-07-17 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors |
| WO2001010462A1 (en) | 1999-08-11 | 2001-02-15 | Idec Pharmaceuticals Corporation | Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies |
| KR20030019328A (ko) * | 2000-03-24 | 2003-03-06 | 아이박스 리서치 인코포레이티드 | 탁산-기저 조성물 및 이를 이용한 방법 |
| US6982253B2 (en) * | 2002-06-05 | 2006-01-03 | Supergen, Inc. | Liquid formulation of decitabine and use of the same |
| KR101792651B1 (ko) * | 2004-05-14 | 2017-11-20 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 아우로라 키나아제의 억제에 의해 유사분열 진행을 억제하기 위한 화합물 및 그 화합물을 포함하는 약학적 조성물 |
| US20070104785A1 (en) * | 2005-07-29 | 2007-05-10 | Navale Suryakant V | Tablets of linezolid form iii and processes for their preparation |
| WO2007076348A2 (en) * | 2005-12-23 | 2007-07-05 | Smithkline Beecham Corporation | Azaindole inhibitors of aurora kinases |
| CA2656393A1 (en) | 2006-06-30 | 2008-01-10 | Schering Corporation | Method of using substituted piperidines that increase p53 activity |
| BRPI0715423A2 (pt) * | 2006-07-21 | 2013-07-02 | Novartis Ag | formulaÇÕes para Éteres de benzimidazolil piridila |
| WO2008021038A2 (en) | 2006-08-09 | 2008-02-21 | Millennium Pharmaceuticals, Inc. | Pyridobenzazepine compounds and methods for inhibiting mitotic progression |
| CL2007003244A1 (es) * | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
| US20090203671A1 (en) * | 2007-11-27 | 2009-08-13 | Abbott Laboratories | Method of treating cancer |
| CN102264368B (zh) * | 2008-12-22 | 2014-09-10 | 米伦纽姆医药公司 | 极光激酶抑制剂与抗cd20抗体的组合 |
| JO3635B1 (ar) * | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
| JO3434B1 (ar) | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
| WO2011103089A1 (en) * | 2010-02-19 | 2011-08-25 | Millennium Pharmaceuticals, Inc. | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6--methoxyphenyl)-5h -pyrimido[5,4-d][2]benzazepin-2yl]amino}-2-methoxybenzoate |
-
2010
- 2010-07-26 JO JOP/2010/0264A patent/JO3434B1/ar active
- 2010-07-28 BR BR112012002265A patent/BR112012002265B8/pt active IP Right Grant
- 2010-07-28 MX MX2012001196A patent/MX2012001196A/es not_active Application Discontinuation
- 2010-07-28 MX MX2015002869A patent/MX348197B/es unknown
- 2010-07-28 US US12/844,920 patent/US20110039826A1/en not_active Abandoned
- 2010-07-28 AU AU2010276741A patent/AU2010276741B2/en active Active
- 2010-07-28 UA UAA201202214A patent/UA110463C2/ru unknown
- 2010-07-28 WO PCT/US2010/002109 patent/WO2011014248A1/en not_active Ceased
- 2010-07-28 EP EP10739413.2A patent/EP2459173B1/en active Active
- 2010-07-28 IN IN1237DEN2012 patent/IN2012DN01237A/en unknown
- 2010-07-28 EA EA201270205A patent/EA025277B1/ru unknown
- 2010-07-28 KR KR1020127004651A patent/KR101762285B1/ko active Active
- 2010-07-28 GE GEAP201012599A patent/GEP201606513B/en unknown
- 2010-07-28 CA CA2769531A patent/CA2769531C/en active Active
- 2010-07-28 CN CN2010800415230A patent/CN102548539A/zh active Pending
- 2010-07-28 JP JP2012522810A patent/JP2013500965A/ja active Pending
- 2010-07-28 NZ NZ59809610A patent/NZ598096A/en unknown
- 2010-07-28 SG SG10201404483VA patent/SG10201404483VA/en unknown
- 2010-07-28 PE PE2012000132A patent/PE20120788A1/es not_active Application Discontinuation
- 2010-07-28 MY MYPI2012000438A patent/MY174084A/en unknown
- 2010-07-28 SG SG2012005401A patent/SG177751A1/en unknown
- 2010-07-28 CN CN201410112836.0A patent/CN103893186B/zh active Active
- 2010-07-30 AR ARP100102812 patent/AR077436A1/es not_active Application Discontinuation
- 2010-07-30 TW TW099125531A patent/TWI522357B/zh active
- 2010-08-02 UY UY32822A patent/UY32822A/es not_active Application Discontinuation
-
2012
- 2012-01-27 TN TNP2012000046A patent/TN2012000046A1/en unknown
- 2012-01-30 IL IL217839A patent/IL217839A/en active IP Right Grant
- 2012-01-31 CL CL2012000261A patent/CL2012000261A1/es unknown
- 2012-02-08 ZA ZA2012/00944A patent/ZA201200944B/en unknown
- 2012-02-09 CO CO12022583A patent/CO6612185A2/es not_active Application Discontinuation
- 2012-02-16 MA MA34640A patent/MA33533B1/fr unknown
- 2012-02-17 CR CR20120084A patent/CR20120084A/es unknown
- 2012-02-29 EC ECSP12011703 patent/ECSP12011703A/es unknown
-
2013
- 2013-06-11 US US13/914,705 patent/US9127011B2/en active Active
-
2015
- 2015-02-05 JP JP2015021023A patent/JP6014695B2/ja active Active
- 2015-08-28 US US14/838,878 patent/US9504693B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6612185A2 (es) | Composiciones famacéuticas para el tratamiento del cáncer y otras enfermedades o transtornos | |
| CY1124928T1 (el) | Αναστολεις πυραζολυλο κινοξαλινο κινασης | |
| CY1116424T1 (el) | Παραγωγο αδενινης ως αναστολεας ρι3κ | |
| MX2013006591A (es) | Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas. | |
| EA201691454A1 (ru) | Композиции придопидина модифицированного высвобождения | |
| WO2012142511A3 (en) | Orthomolecular compositions and their use in stabilizing the extracellular matrix | |
| ECSP099445A (es) | Quinazolinas para la inhibición de pdk1 | |
| MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
| MX2015012006A (es) | Inhibidores de bromodominio tetraciclicos. | |
| IN2014MN00948A (enExample) | ||
| IN2012DN02735A (enExample) | ||
| IN2012DN02730A (enExample) | ||
| IN2012DN00754A (enExample) | ||
| CL2014000543A1 (es) | Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
| EP3686200A3 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| GB201209613D0 (en) | New compounds | |
| EA201000091A1 (ru) | ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K | |
| CL2008000020A1 (es) | Compuestos derivados de 2,4-dianilinopirimidinas sustituidas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y tumores malignos. | |
| DOP2012000063A (es) | (heteroarilmetil) tiohidantoinas sustituidas como drogas anticancer | |
| CL2013000018A1 (es) | Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros. | |
| CL2008002243A1 (es) | Compuestos derivados de 2-pirazolamino-1,3,5-triazina, inhibidores de kinasa jak; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer. | |
| BR112016015236A8 (pt) | composto,composição farmacêutica,uso de um composto,método de inibição e método para tratar ou aliviar a gravidade de uma doença. | |
| ECSP088874A (es) | Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual | |
| MX2015016425A (es) | Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades. | |
| SG10201805267UA (en) | Piperazine derivatives having multimodal activity against pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20190214 |